By Dean Seal
Avantor lowered its revenue outlook for the year after waning demand in the government- and education-related end markets for one of its segments cut into first-quarter sales.
The Radnor, Pa., biopharma supplier posted a profit of $64.5 million, or 9 cents a share, compared with $60.4 million, or 9 cents a share, in the same period a year earlier.
Stripping out one-time items, adjusted earnings were 23 cents a share, in line with the consensus estimate of analysts polled by FactSet.
Revenue slid 6% to $1.58 billion, below analyst projections for $1.61 billion, according to FactSet.
The company said its lab-solutions business saw a drop in demand, particularly for its education and government end markets, due to policy changes from the new presidential administration.
As a result, the company is lowering its guidance. It now expects organic revenue to come in either up 1%, down 1% or somewhere in between. It previously guided for a 1%-to-3% gain.
"We are implementing a comprehensive strategy to strengthen our lab solutions segment and are committed to moving with urgency to improve performance across the business," Chief Executive Michael Stubblefield said.
The company also said Friday that Stubblefield intends to step down and will resign from his CEO position whenever his successor is found.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
April 25, 2025 06:47 ET (10:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。